Abstract
Heart failure (HF) is common and growing clinical and economic problem associated with frequent admission to hospital and poor prognosis. At present beta adrenoreceptor blockers, ACE inhibitors, ATII receptor antagonists, diuretics and digitalis are used extensively in the treatment of patient with chronic heart failure.
However, as the disease progresses, often hospitalisation and more agressive therapy is required to reduce congestion. In this article new strategies in the treatment of severe HF (selective endotelin receptor A blockers, eplerenone as a selective aldosteron blocker, inotropic agent levosimendan, selective antagonists of the vasoperessin V2 receptor and new mechanical circulatory assistance) are reported.